Study of the Vascular Response to Percutaneous Coronary Intervention in Patients With Non-ST-elevation Acute Coronary Syndromes Using Intravascular Blood Sampling
NCT ID: NCT03300167
Last Updated: 2021-03-17
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
WITHDRAWN
Clinical Phase
NA
Study Classification
INTERVENTIONAL
Study Start Date
2017-11-30
Study Completion Date
2020-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This interventional study is using the PlaqueTec LBS will enrol participants already undergoing coronary angiography as a component of their standard care for NSTE-ACS. The study will involve no change to medication or overall treatment strategy, but will involve an additional procedure: use of a novel CE-marked coronary artery catheter to obtain spatially-separated intravascular samples for laboratory measurement. As a safety objective and as a component of the required post-marketing surveillance, OCT will be performed before and after deployment of the LBS, and patients will be followed up for a significant period of time by the investigator's post-procedure.
Individual participants will not gain directly from taking part in the study, other than having access to more prolonged follow up than is standard. However, new insights will be gained into the microenvironment surrounding a ruptured plaque in NSTE-ACS, which has the potential to benefit patients with CAD in the future through greater understanding of the effects of current therapy, development of new treatment strategies and methods of assessing the efficacy of those treatment strategies.
Use of the LBS and the associated OCT examinations will require additional angiographic screening and therefore lead to greater exposure to radiation and higher contrast load. This will be closely monitored as per Trust policies in line with IRMER and local radiological guidelines. Patients at particular risk of developing complications from increased exposure to radiation and contrast (eg. those who are pregnant and those with abnormal baseline renal function) will not be included in order to minimise adverse effects.
Individual participants will not gain directly from taking part in the study, other than having access to more prolonged follow up than is standard. However, new insights will be gained into the microenvironment surrounding a ruptured plaque in NSTE-ACS, which has the potential to benefit patients with CAD in the future through greater understanding of the effects of current therapy, development of new treatment strategies and methods of assessing the efficacy of those treatment strategies.
Use of the LBS and the associated OCT examinations will require additional angiographic screening and therefore lead to greater exposure to radiation and higher contrast load. This will be closely monitored as per Trust policies in line with IRMER and local radiological guidelines. Patients at particular risk of developing complications from increased exposure to radiation and contrast (eg. those who are pregnant and those with abnormal baseline renal function) will not be included in order to minimise adverse effects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of DLBS1033 After Primary PCI in Patients With STE-ACS
NCT02976701
ST Elevation Myocardial Infarction
TERMINATED
PHASE2/PHASE3
Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients
NCT02070471
ST-segment Elevation Myocardial Infarction
COMPLETED
PHASE2
MT1002 Phase II Study in ACS Patients With PCI
NCT04723186
Acute Coronary Syndrome
TERMINATED
PHASE2
Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease
NCT00584896
Coronary Artery Disease
TERMINATED
PHASE3
Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients
NCT02770664
ST-segment Elevation Myocardial Infarction
UNKNOWN
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This clinical protocol will be subject to peer review according to standard local procedures, including independent scientific review by the Scientific Advisory Board of the Clinical Research Facility, Sheffield Teaching Hospitals NHS Foundation Trust; the Clinical Research Office, Sheffield Teaching Hospitals NHS Foundation Trust; and the Research Ethics Committee. The study will be a single-centre study including use of a CE-marked medical device to obtain samples, conducted at Cardiology and Cardiothoracic Surgery Directorate, Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust.
Patients with a diagnosis of NSTE-ACS, receiving DAPT with a combination of aspirin and ticagrelor or prasugrel, and listed either for coronary angiography with the intention of proceeding to PCI or for PCI following coronary angiography at a referring hospital, will be approached and their informed consent sought for this study. 18 patients found to have culprit significant proximal epicardial coronary artery stenosis suitable for PCI, meeting all the inclusion and exclusion criteria, will proceed to have platelet function testing and LBS measurements. Blood will be taken from the arterial sheath or guide catheter and baseline platelet function testing will be performed (VerifyNow P2Y12 assay; light transmittance aggregometry with ADP and arachidonic acid as agonists; and serum thromboxane B2 assay). Balloon predilatation prior to stent deployment will be a mandatory requirement for the study. Following balloon predilatation, the LBS will be deployed across the treated lesion and blood sampling will be performed proximal and distal to the lesion at approximately 5 minutes after predilatation. The following assays will be performed on the sampled blood:
1. Plasma levels of soluble markers of thrombosis and inflammation including prothrombin fragments 1 and 2, fibrinopeptide A, soluble P-selectin and thromboxane B2.
2. Platelet surface P-selectin expression
3. Leukocyte surface CD11b expression Blood taken prior to PCI will also be sent to the local laboratory for measurement of the cardiac-specific marker high-sensitivity troponin T and a further venous blood sample will be collected at 6 hours after PCI to measure any rise in troponin in order to correlate this with thrombin generation. A rise of 5 times the upper limit of normal of troponin following PCI in the context of chest pain or diagnostic ECG changes will be used to define peri-procedural myocardial infarction per the Universal Definition of Myocardial Infarction (Thygesen, Alpert et al. 2012).
OCT of the culprit lesion, as well as the coronary artery proximal and distal to this, will be performed before and after the deployment of the LBS to assess any topographical changes to the vessel wall caused by the LBS and provide information on target lesion morphology.
Clinical outcomes will be reviewed and AEs (including MACE) will be recorded at 6 hours, 30 days and 6 months after the procedure. At the 6-hour visit, patients will be assessed by a medically-qualified investigator and have a blood sample collected for troponin T level and ECG performed. At the 30-day visit, patients will receive a full clinical assessment by a medically-qualified investigator, have DAPT compliance assessed, be asked about angina intensity, have any MACE or other AEs recorded and have an ECG. A telephone contact will be made at 6 months after PCI to assess any MACE or other AEs, angina intensity and DAPT compliance.
Patients with a diagnosis of NSTE-ACS, receiving DAPT with a combination of aspirin and ticagrelor or prasugrel, and listed either for coronary angiography with the intention of proceeding to PCI or for PCI following coronary angiography at a referring hospital, will be approached and their informed consent sought for this study. 18 patients found to have culprit significant proximal epicardial coronary artery stenosis suitable for PCI, meeting all the inclusion and exclusion criteria, will proceed to have platelet function testing and LBS measurements. Blood will be taken from the arterial sheath or guide catheter and baseline platelet function testing will be performed (VerifyNow P2Y12 assay; light transmittance aggregometry with ADP and arachidonic acid as agonists; and serum thromboxane B2 assay). Balloon predilatation prior to stent deployment will be a mandatory requirement for the study. Following balloon predilatation, the LBS will be deployed across the treated lesion and blood sampling will be performed proximal and distal to the lesion at approximately 5 minutes after predilatation. The following assays will be performed on the sampled blood:
1. Plasma levels of soluble markers of thrombosis and inflammation including prothrombin fragments 1 and 2, fibrinopeptide A, soluble P-selectin and thromboxane B2.
2. Platelet surface P-selectin expression
3. Leukocyte surface CD11b expression Blood taken prior to PCI will also be sent to the local laboratory for measurement of the cardiac-specific marker high-sensitivity troponin T and a further venous blood sample will be collected at 6 hours after PCI to measure any rise in troponin in order to correlate this with thrombin generation. A rise of 5 times the upper limit of normal of troponin following PCI in the context of chest pain or diagnostic ECG changes will be used to define peri-procedural myocardial infarction per the Universal Definition of Myocardial Infarction (Thygesen, Alpert et al. 2012).
OCT of the culprit lesion, as well as the coronary artery proximal and distal to this, will be performed before and after the deployment of the LBS to assess any topographical changes to the vessel wall caused by the LBS and provide information on target lesion morphology.
Clinical outcomes will be reviewed and AEs (including MACE) will be recorded at 6 hours, 30 days and 6 months after the procedure. At the 6-hour visit, patients will be assessed by a medically-qualified investigator and have a blood sample collected for troponin T level and ECG performed. At the 30-day visit, patients will receive a full clinical assessment by a medically-qualified investigator, have DAPT compliance assessed, be asked about angina intensity, have any MACE or other AEs recorded and have an ECG. A telephone contact will be made at 6 months after PCI to assess any MACE or other AEs, angina intensity and DAPT compliance.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Non ST Segment Elevation Acute Coronary Syndrome
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
DEVICE_FEASIBILITY
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CE-marked coronary artery catheter
use of a novel CE-marked coronary artery catheter to obtain spatially-separated intravascular samples for laboratory measurement.
Group Type
EXPERIMENTAL
The Liquid Biopsy System
Intervention Type
DEVICE
The Liquid Biopsy System is a single use percutaneously-delivered coronary blood sampling device designed to collect blood samples from within a target coronary artery so that the blood can be analysed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The Liquid Biopsy System
The Liquid Biopsy System is a single use percutaneously-delivered coronary blood sampling device designed to collect blood samples from within a target coronary artery so that the blood can be analysed.
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged over 18 years
* Admitted to hospital with non-ST-elevation ACS and plan for either coronary angiography with a view to PCI if appropriate or PCI following coronary angiography at a referring hospital
* Current treatment with aspirin and ticagrelor or, if ticagrelor is not tolerated, prasugrel (DAPT)
* Ability to give informed consent
* Admitted to hospital with non-ST-elevation ACS and plan for either coronary angiography with a view to PCI if appropriate or PCI following coronary angiography at a referring hospital
* Current treatment with aspirin and ticagrelor or, if ticagrelor is not tolerated, prasugrel (DAPT)
* Ability to give informed consent
Exclusion Criteria
* Treatment with antiplatelet medication apart from aspirin, ticagrelor, prasugrel or clopidogrel in the last 10 days (e.g. dipyridamole, abciximab, tirofiban).
* Planned use of a glycoprotein IIb/IIIa antagonist for the PCI procedure.
* Patients with haemodynamic instability, shock or angiographic evidence of intracoronary thrombus.
* Current use of an oral anticoagulant (e.g. warfarin, dabigatran, rivaroxaban, apixaban).
* Clinically significant liver disease.
* Contraindication or allergy to unfractionated heparin.
* Receiving immunosuppressant medication (eg. cyclosporin, tacrolimus, mycophenolate, azathioprine).
* Administration of doses of low molecular weight heparin or fondaparinux in the 12 hours preceding PCI.
* Known severe left ventricular dysfunction (ejection fraction \<30%).
* Culprit lesion in left main coronary artery.
* Women of childbearing potential unless pregnancy has been excluded during the index hospital admission.
* Known serum creatinine above upper limit of local reference range.
* Subjects with known active chronic inflammatory disease, e.g. systemic lupus erythematosus, rheumatoid arthritis, seropositive arthropathies and known seropositivity to HIV, Hepatitis B or Hepatitis C.
* Severely diseased, excessively tortuous or calcified coronary vessels that increase the risk of snaring the LBS.
* Culprit lesion in a coronary vessel with a reference diameter of less than 2.5 mm.
* Need to cross a region of coronary vessel that contains a stent.
* Evidence of ongoing sepsis.
* Receiving a non-steroidal anti-inflammatory drug (NSAID) apart from aspirin, including selective COX2 inhibitors ('coxibs') and including regular or intermittent/as required use.
* Receiving a strong inhibitor of CYP3A4 (eg, ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin \[but not erythromycin or azithromycin\], nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atanazavir, or over 1 litre daily of grapefruit juice).
* Receiving simvastatin or lovastatin at doses higher than 40 mg daily.
* Receiving a CYP3A substrate with a narrow therapeutic index (e.g. cyclosporine or quinidine).
* Receiving a strong inducer of CYP3A (e.g. rifampin/rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital).
* Current or recent (within 30 days) participation in a clinical trial of a drug or device or any other clinical study that might influence the results or safety of the study.
* Any factor precluding ability to comply with follow-up.
* Any other factor judged by the investigator or treating physician to preclude enrolment in the study.
* Planned use of a glycoprotein IIb/IIIa antagonist for the PCI procedure.
* Patients with haemodynamic instability, shock or angiographic evidence of intracoronary thrombus.
* Current use of an oral anticoagulant (e.g. warfarin, dabigatran, rivaroxaban, apixaban).
* Clinically significant liver disease.
* Contraindication or allergy to unfractionated heparin.
* Receiving immunosuppressant medication (eg. cyclosporin, tacrolimus, mycophenolate, azathioprine).
* Administration of doses of low molecular weight heparin or fondaparinux in the 12 hours preceding PCI.
* Known severe left ventricular dysfunction (ejection fraction \<30%).
* Culprit lesion in left main coronary artery.
* Women of childbearing potential unless pregnancy has been excluded during the index hospital admission.
* Known serum creatinine above upper limit of local reference range.
* Subjects with known active chronic inflammatory disease, e.g. systemic lupus erythematosus, rheumatoid arthritis, seropositive arthropathies and known seropositivity to HIV, Hepatitis B or Hepatitis C.
* Severely diseased, excessively tortuous or calcified coronary vessels that increase the risk of snaring the LBS.
* Culprit lesion in a coronary vessel with a reference diameter of less than 2.5 mm.
* Need to cross a region of coronary vessel that contains a stent.
* Evidence of ongoing sepsis.
* Receiving a non-steroidal anti-inflammatory drug (NSAID) apart from aspirin, including selective COX2 inhibitors ('coxibs') and including regular or intermittent/as required use.
* Receiving a strong inhibitor of CYP3A4 (eg, ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin \[but not erythromycin or azithromycin\], nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atanazavir, or over 1 litre daily of grapefruit juice).
* Receiving simvastatin or lovastatin at doses higher than 40 mg daily.
* Receiving a CYP3A substrate with a narrow therapeutic index (e.g. cyclosporine or quinidine).
* Receiving a strong inducer of CYP3A (e.g. rifampin/rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital).
* Current or recent (within 30 days) participation in a clinical trial of a drug or device or any other clinical study that might influence the results or safety of the study.
* Any factor precluding ability to comply with follow-up.
* Any other factor judged by the investigator or treating physician to preclude enrolment in the study.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sheffield Teaching Hospitals NHS Foundation Trust
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, South Yorkshire, United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United Kingdom
References
Explore related publications, articles, or registry entries linked to this study.
Kavanagh TG, Griffiths NJ, Todd I. Psoas abscess and Crohn's disease. J R Soc Med. 1979 Aug;72(8):612-3. doi: 10.1177/014107687907200813. No abstract available.
Reference Type
BACKGROUND
Caine ED, Polinsky RJ. Haloperidol-induced dysphoria in patients with Tourette syndrome. Am J Psychiatry. 1979 Sep;136(9):1216-7. doi: 10.1176/ajp.136.9.1216. No abstract available.
Reference Type
BACKGROUND
Timmermans PJ, Vossen JM. Prey catching in the archer fish: does the fish use a learned correction for refraction? Behav Processes. 2000 Oct 26;52(1):21-34. doi: 10.1016/s0376-6357(00)00107-8.
Reference Type
BACKGROUND
Suzuki N, Kato M, Dohmori R. [Synthesis of antimicrobial agents. II. Synthesis of 1,8-naphthyridine derivatives and their activities against Trichomonas vaginalis (author's transl)]. Yakugaku Zasshi. 1979 Feb;99(2):155-64. doi: 10.1248/yakushi1947.99.2_155. No abstract available. Japanese.
Reference Type
BACKGROUND
Lai Y, Xu DP. [Study on the chemical structure from the roots of Actinidia deliciosa]. Zhong Yao Cai. 2007 Feb;30(2):166-8. Chinese.
Reference Type
BACKGROUND
[Animal husbandry (the main trends)]. Veterinariia. 1977 Jun;(6):LL'*23. No abstract available. Russian.
Reference Type
BACKGROUND
May A. The Confidential Enquiries into Maternal Deaths 1997-1999: what can we learn? Int J Obstet Anesth. 2002 Jul;11(3):153-5. doi: 10.1054/ijoa.2002.0957. No abstract available.
Reference Type
BACKGROUND
Falgoust DL. Hospital security over the years: keeping up with the changes. J Healthc Prot Manage. 2002 Summer;18(2):115-22.
Reference Type
BACKGROUND
da Costa MC. [Correlation between serum DDT levels and the diphtheria antibody titer in girls]. Rev Saude Publica. 1979 Mar;13(1):32-42. doi: 10.1590/s0034-89101979000100005. No abstract available. Portuguese.
Reference Type
BACKGROUND
Courtney LD. Respiratory distress syndrome. Br Med J. 1977 Mar 5;1(6061):639. doi: 10.1136/bmj.1.6061.639-a. No abstract available.
Reference Type
BACKGROUND
Farng E, Hunt SA, Rose DJ, Sherman OH. Anterior cruciate ligament radiofrequency thermal shrinkage: a short-term follow-up. Arthroscopy. 2005 Sep;21(9):1027-33. doi: 10.1016/j.arthro.2005.05.015.
Reference Type
BACKGROUND
Costa M, Pecci L, Pensa B, Cannella C. Hydrogen peroxide involvement in the rhodanese inactivation by dithiothreitol. Biochem Biophys Res Commun. 1977 Sep 23;78(2):596-603. doi: 10.1016/0006-291x(77)90221-2. No abstract available.
Reference Type
BACKGROUND
Mertz D, Johnstone J, Loeb M. Does duration of perioperative antibiotic prophylaxis matter in cardiac surgery? A systematic review and meta-analysis. Ann Surg. 2011 Jul;254(1):48-54. doi: 10.1097/SLA.0b013e318214b7e4.
Reference Type
BACKGROUND
Zagury D, Chaouat G, Morgan DA, Voisin GA. [Identification of cytotoxic cells responsible for lysis of target cells pretreated with concanavalin A in spleen populations of pregnant mice with suppressive activity]. C R Seances Acad Sci D. 1979 May 7;288(17):1343-6. French.
Reference Type
BACKGROUND
Donnelly N, Hadwin JA, Cave K, Stevenage S. Perceptual dominance of oriented faces mirrors the distribution of orientation tunings in inferotemporal neurons. Brain Res Cogn Brain Res. 2003 Oct;17(3):771-80. doi: 10.1016/s0926-6410(03)00201-5.
Reference Type
BACKGROUND
Niederer RO, Zappulla DC. Refined secondary-structure models of the core of yeast and human telomerase RNAs directed by SHAPE. RNA. 2015 Feb;21(2):254-61. doi: 10.1261/rna.048959.114. Epub 2014 Dec 15.
Reference Type
BACKGROUND
Megla GK. [A new blood gas analyzer Corning model 175]. Med Lab (Stuttg). 1976 Jan;29(1):12-22. No abstract available. German.
Reference Type
BACKGROUND
Pongrakhananon V, Luanpitpong S, Stueckle TA, Wang L, Nimmannit U, Rojanasakul Y. Carbon nanotubes induce apoptosis resistance of human lung epithelial cells through FLICE-inhibitory protein. Toxicol Sci. 2015 Feb;143(2):499-511. doi: 10.1093/toxsci/kfu251. Epub 2014 Nov 19.
Reference Type
BACKGROUND
Statement on flexible patterns of nursing education. ANA Publ. 1978;(NE-3):i-iv, 1-13. No abstract available.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STH19267
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Very Early Versus Delayed Angiography +/- Intervention on Outcomes in Patients With NSTEMI
NCT03707314
TERMINATED
NA
A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)
NCT00060554
WITHDRAWN
PHASE2
Antiplatelet Therapy After Successful Percutaneous Coronary Intervention for Chronically Occluded Coronary Artery
NCT06175377
NOT_YET_RECRUITING
NA
The Relationship Between MPV,PDW,PFT and ST Segment Resolution in STEMI Patients Treated With Thrombolytic or Primary PCI
NCT03267199
WITHDRAWN
Assessment of Thrombogenicity in Acute Coronary Syndrome
NCT00728286
COMPLETED
DCB Under the Guidance of OCT in STEMI
NCT05680051
UNKNOWN
NA
Platelet Function Monitoring in Patients With Acute Myocardial Infarction
NCT01353261
COMPLETED
Randomised EValuation of Therapies for microvAscuLar Injury in STEACS
NCT06935383
NOT_YET_RECRUITING
PHASE2
Intra-aortic Balloon Pump in Extensive Myocardial Infarction With Persistent Ischemia
NCT02125526
COMPLETED
NA
A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.
NCT03998319
RECRUITING
PHASE3
Prokinecitine in Acute Myocardial Infarction
NCT02021487
TERMINATED
Remote Ischemic Perconditioning in Patients With ST-segment Elevation Myocardial Infarction
NCT02164695
COMPLETED
NA
Evaluation in STEMI Patients Using FDY-5301
NCT04837001
COMPLETED
PHASE3
AngioJET Thrombectomy and STENTing for Treatment of Acute Myocardial Infarction
NCT00275990
COMPLETED
PHASE4
Treatment of Slow-flow After Primary Percutaneous Coronary Intervention With Flow-mediated Hyperemia
NCT04685941
COMPLETED
NA
Circulating PRCP in STEMI Patients Undergoing Primary PCI
NCT02772133
COMPLETED
Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes
NCT03113773
COMPLETED
PHASE1/PHASE2
PICSO in Patients With STEMI Treated by Primary Percutaneous Coronary Intervention
NCT01493037
COMPLETED
NA
Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treatment
NCT00968383
TERMINATED
NA
Drug-coated Balloon Versus Drug-eluting Stent in Acute Myocardial Infarction
NCT02219802
UNKNOWN
NA
Percutaneous Revascularization in Infarction With Late Presentation and Absence of Viability: Effects on Left Ventricular Remodeling and Contractility
NCT05160311
UNKNOWN
NA
Pilot Study on Shear-induced Platelet Aggregation in Acute Coronary Syndromes
NCT00299143
COMPLETED
DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization
NCT02146664
WITHDRAWN
PHASE2/PHASE3
Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI
NCT00586820
COMPLETED
PHASE2